How to buy Liminal BioSciences stock - 17 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Liminal BioSciences stock

Own Liminal BioSciences stock in just a few minutes.

Liminal BioSciences Inc is a biotechnology business based in the US. Liminal BioSciences shares (LMNL) are listed on the NASDAQ and all prices are listed in US Dollars. Liminal BioSciences employs 251 staff and has a trailing 12-month revenue of around USD$3.3 million.

How to buy shares in Liminal BioSciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Liminal BioSciences. Find the stock by name or ticker symbol: LMNL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Liminal BioSciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Liminal BioSciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Liminal BioSciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Liminal BioSciences share price

Use our graph to track the performance of LMNL stocks over time.

Liminal BioSciences shares at a glance

Information last updated 2021-04-13.
52-week rangeUSD$3.51 - USD$21.29
50-day moving average USD$4.4538
200-day moving average USD$5.2961
Wall St. target priceUSD$9.98
PE ratio 2.3681
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-12.8072

Buy Liminal BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Liminal BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Liminal BioSciences under- or over-valued?

Valuing Liminal BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Liminal BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Liminal BioSciences's P/E ratio

Liminal BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Liminal BioSciences shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Liminal BioSciences financials

Revenue TTM USD$3.3 million
Gross profit TTM USD$-55,542,000
Return on assets TTM -41.58%
Return on equity TTM -222.18%
Profit margin 0%
Book value N/A
Market capitalisation USD$123.1 million

TTM: trailing 12 months

Shorting Liminal BioSciences shares

There are currently 285,673 Liminal BioSciences shares held short by investors – that's known as Liminal BioSciences's "short interest". This figure is 4.8% down from 300,041 last month.

There are a few different ways that this level of interest in shorting Liminal BioSciences shares can be evaluated.

Liminal BioSciences's "short interest ratio" (SIR)

Liminal BioSciences's "short interest ratio" (SIR) is the quantity of Liminal BioSciences shares currently shorted divided by the average quantity of Liminal BioSciences shares traded daily (recently around 529024.07407407). Liminal BioSciences's SIR currently stands at 0.54. In other words for every 100,000 Liminal BioSciences shares traded daily on the market, roughly 540 shares are currently held short.

However Liminal BioSciences's short interest can also be evaluated against the total number of Liminal BioSciences shares, or, against the total number of tradable Liminal BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Liminal BioSciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Liminal BioSciences shares in existence, roughly 10 shares are currently held short) or 0.0299% of the tradable shares (for every 100,000 tradable Liminal BioSciences shares, roughly 30 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Liminal BioSciences.

Find out more about how you can short Liminal BioSciences stock.

Liminal BioSciences share dividends

We're not expecting Liminal BioSciences to pay a dividend over the next 12 months.

Have Liminal BioSciences's shares ever split?

Liminal BioSciences's shares were split on a 1:1000 basis on 4 July 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Liminal BioSciences shares – just the quantity. However, indirectly, the new 99900% higher share price could have impacted the market appetite for Liminal BioSciences shares which in turn could have impacted Liminal BioSciences's share price.

Liminal BioSciences share price volatility

Over the last 12 months, Liminal BioSciences's shares have ranged in value from as little as $3.51 up to $21.29. A popular way to gauge a stock's volatility is its "beta".

LMNL.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Liminal BioSciences's is 1.4352. This would suggest that Liminal BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Liminal BioSciences overview

Liminal BioSciences Inc. , a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site